ANC 0 3 0 3 B-clinical_variable
( 4 5 4 5 I-clinical_variable
Absolute 5 13 5 13 I-clinical_variable
neutrophil 14 24 14 24 I-clinical_variable
count 25 30 25 30 I-clinical_variable
) 30 31 30 31 I-clinical_variable
> 32 33 32 33 O
1,000 33 38 33 38 B-lower_bound
/ 38 39 38 39 I-lower_bound
mcL 39 42 39 42 I-lower_bound
( 43 44 43 44 I-lower_bound
microliter 44 54 44 54 I-lower_bound
) 54 55 54 55 I-lower_bound

Age 0 3 56 59 B-age
> 4 5 60 61 O
18 6 8 62 64 B-lower_bound
years 9 14 65 70 I-lower_bound

All 0 3 71 74 O
subjects 4 12 75 83 O
must 13 17 84 88 O
have 18 22 89 93 O
previously 23 33 94 104 O
received 34 42 105 113 O
trastuzumab 43 54 114 125 B-treatment
or 55 57 126 128 O
other 58 63 129 134 O
HER2 64 68 135 139 B-treatment
targeted 69 77 140 148 I-treatment
therapies 78 87 149 158 I-treatment

All 0 3 159 162 O
subjects 4 12 163 171 O
must 13 17 172 176 O
have 18 22 177 181 O
recurrent 23 32 182 191 B-cancer
or 33 35 192 194 I-cancer
metastatic 36 46 195 205 I-cancer
HER2 47 51 206 210 I-cancer
- 51 52 210 211 I-cancer
positive 52 60 211 219 I-cancer
breast 61 67 220 226 I-cancer
cancer 68 74 227 233 I-cancer

Baseline 0 8 234 242 O
HIV 9 12 243 246 B-chronic_disease
screening 13 22 247 256 O

Baseline 0 8 257 265 B-clinical_variable
neuropathy 9 19 266 276 I-clinical_variable
> 20 21 277 278 O
grade 21 26 278 283 B-lower_bound
1 27 28 284 285 I-lower_bound

Chemotherapy 0 12 286 298 B-treatment
, 12 13 298 299 O
radiotherapy 14 26 300 312 B-treatment
or 27 29 313 315 O
hormonal 30 38 316 324 B-treatment
therapy 39 46 325 332 I-treatment
within 47 53 333 339 O
3 54 55 340 341 B-upper_bound
weeks 56 61 342 347 I-upper_bound
( 62 63 348 349 O
6 64 65 350 351 O
weeks 66 71 352 357 O
for 72 75 358 361 O
nitrosoureas 76 88 362 374 B-treatment
, 88 89 374 375 O
mitomycin 90 99 376 385 B-treatment
C 100 101 386 387 I-treatment
or 102 104 388 390 O
bevacizumab 105 116 391 402 B-treatment
) 116 117 402 403 O

Known 0 5 404 409 O
active 6 12 410 416 O
CNS 13 16 417 420 B-cancer
metastases 17 27 421 431 I-cancer
or 28 30 432 434 O
carcinomatous 31 44 435 448 B-cancer
meningitis 45 55 449 459 I-cancer

Known 0 5 460 465 O
positive 6 14 466 474 O
for 15 18 475 478 O
human 19 24 479 484 B-chronic_disease
immunodeficiency 25 41 485 501 I-chronic_disease
virus 42 47 502 507 I-chronic_disease
( 48 49 508 509 I-chronic_disease
HIV 49 52 509 512 I-chronic_disease
) 52 53 512 513 I-chronic_disease

Platelets 0 9 514 523 B-clinical_variable
> 10 11 524 525 O
100,000 11 18 525 532 B-lower_bound
/ 18 19 532 533 I-lower_bound
mcL 19 22 533 536 I-lower_bound

Pregnant 0 8 537 545 B-pregnancy

RB 0 2 546 548 B-treatment
( 3 4 549 550 I-treatment
Retinoblastoma 4 18 550 564 I-treatment
protein)-proficiency 19 39 565 585 I-treatment
is 40 42 586 588 O
determined 43 53 589 599 O
by 54 56 600 602 O
tumor 57 62 603 608 B-treatment
biopsy 63 69 609 615 I-treatment
demonstrating 70 83 616 629 O
RB 84 86 630 632 O
normal 87 93 633 639 O
and 94 97 640 643 O
p16in4a 98 105 644 651 O
low 106 109 652 655 O
by 110 112 656 658 O
immunohistochemistry 113 133 659 679 O

RB 0 2 680 682 O
proficiency 3 14 683 694 O
means 15 20 695 700 O
that 21 25 701 705 O
there 26 31 706 711 O
is 32 34 712 714 O
an 35 37 715 717 O
intact 38 44 718 724 O
RB 45 47 725 727 O
pathway 48 55 728 735 O
indicative 56 66 736 746 O
of 67 69 747 749 O
responsiveness 70 84 750 764 O
to 85 87 765 767 O
PD-0332991 88 98 768 778 O
. 98 99 778 779 O
RB 100 102 780 782 O
staining 103 111 783 791 O
is 112 114 792 794 O
scored 115 121 795 801 O
on 122 124 802 804 O
an 125 127 805 807 O
absent 128 134 808 814 O
( 135 136 815 816 O
no 136 138 816 818 O
nuclear 139 146 819 826 O
staining 147 155 827 835 O
) 155 156 835 836 O
, 156 157 836 837 O
weak 158 162 838 842 O
( 163 164 843 844 O
nuclear 164 171 844 851 O
staining 172 180 852 860 O
less 181 185 861 865 O
than 186 190 866 870 O
observed 191 199 871 879 O
in 200 202 880 882 O
endothelial 203 214 883 894 O
cells 215 220 895 900 O
and 221 224 901 904 O
stromal 225 232 905 912 O
cells 233 238 913 918 O
surrounding 239 250 919 930 O
the 251 254 931 934 O
tumor 255 260 935 940 B-cancer
) 260 261 940 941 O
, 261 262 941 942 O
positive 263 271 943 951 O
( 272 273 952 953 O
nuclear 273 280 953 960 O
staining 281 289 961 969 O
at 290 292 970 972 O
or 293 295 973 975 O
above 296 301 976 981 O
surrounding 302 313 982 993 O
tissue 314 320 994 1000 O
) 320 321 1000 1001 O
( 322 323 1002 1003 O
0 323 324 1003 1004 O
, 324 325 1004 1005 O
0.5 326 329 1006 1009 O
, 329 330 1009 1010 O
1 331 332 1011 1012 O
respectively 333 345 1013 1025 O
) 345 346 1025 1026 O
. 346 347 1026 1027 O
P16ink4a 348 356 1028 1036 O
is 357 359 1037 1039 O
a 360 361 1040 1041 O
routine 362 369 1042 1049 O
clinical 370 378 1050 1058 O
stain 379 384 1059 1064 O
that 385 389 1065 1069 O
is 390 392 1070 1072 O
scored 393 399 1073 1079 O
using 400 405 1080 1085 O
absent 406 412 1086 1092 O
, 412 413 1092 1093 O
weak 414 418 1094 1098 O
, 418 419 1098 1099 O
positive 420 428 1100 1108 O
, 428 429 1108 1109 O
strong 430 436 1110 1116 O
( 437 438 1117 1118 O
0,1,2,3 438 445 1118 1125 O
respectively 446 458 1126 1138 O
) 458 459 1138 1139 O
. 459 460 1139 1140 O
Tumors 461 467 1141 1147 O
will 468 472 1148 1152 O
be 473 475 1153 1155 O
scored 476 482 1156 1162 O
using 483 488 1163 1168 O
[ 489 490 1169 1170 O
p16]/[RB 490 498 1170 1178 O
] 498 499 1178 1179 O
, 499 500 1179 1180 O
where 501 506 1181 1186 O
a 507 508 1187 1188 O
score 509 514 1189 1194 O
of 515 517 1195 1197 O
less 518 522 1198 1202 O
than 523 527 1203 1207 O
3 528 529 1208 1209 O
is 530 532 1210 1212 O
required 533 541 1213 1221 O
for 542 545 1222 1225 O
inclusion 546 555 1226 1235 O
. 555 556 1235 1236 O
RB 557 559 1237 1239 O
loss 560 564 1240 1244 O
is 565 567 1245 1247 O
expected 568 576 1248 1256 O
to 577 579 1257 1259 O
occur 580 585 1260 1265 O
in 586 588 1266 1268 O
less 589 593 1269 1273 O
than 594 598 1274 1278 O
15 599 601 1279 1281 B-upper_bound
% 601 602 1281 1282 I-upper_bound
of 603 605 1283 1285 O
cases 606 611 1286 1291 O

Subjects 0 8 1292 1300 O
less 9 13 1301 1305 O
than 14 18 1306 1310 O
4 19 20 1311 1312 B-upper_bound
weeks 21 26 1313 1318 I-upper_bound
post 27 31 1319 1323 B-treatment
major 32 37 1324 1329 I-treatment
surgery 38 45 1330 1337 I-treatment

Subjects 0 8 1338 1346 O
must 9 13 1347 1351 O
be 14 16 1352 1354 O
willing 17 24 1355 1362 B-contraception_consent
to 25 27 1363 1365 I-contraception_consent
use 28 31 1366 1369 I-contraception_consent
an 32 34 1370 1372 I-contraception_consent
approved 35 43 1373 1381 I-contraception_consent
form 44 48 1382 1386 I-contraception_consent
of 49 51 1387 1389 I-contraception_consent
birth 52 57 1390 1395 I-contraception_consent
control 58 65 1396 1403 I-contraception_consent
while 66 71 1404 1409 O
on 72 74 1410 1412 O
this 75 79 1413 1417 O
study 80 85 1418 1423 O
and 86 89 1424 1427 O
for 90 93 1428 1431 O
90 94 96 1432 1434 B-upper_bound
days 97 101 1435 1439 I-upper_bound
after 102 107 1440 1445 O
completion 108 118 1446 1456 O

Subjects 0 8 1457 1465 O
must 9 13 1466 1470 O
have 14 18 1471 1475 O
a 19 20 1476 1477 O
performance 21 32 1478 1489 O
status 33 39 1490 1496 O
of 40 42 1497 1499 O
â‰¤ 43 44 1500 1501 O
2 45 46 1502 1503 B-upper_bound
on 47 49 1504 1506 O
the 50 53 1507 1510 O
ECOG 54 58 1511 1515 B-clinical_variable
( 59 60 1516 1517 I-clinical_variable
Eastern 60 67 1517 1524 I-clinical_variable
Cooperative 68 79 1525 1536 I-clinical_variable
Oncology 80 88 1537 1545 I-clinical_variable
Group)Performance 89 106 1546 1563 I-clinical_variable
scale 107 112 1564 1569 I-clinical_variable

Subjects 0 8 1570 1578 O
must 9 13 1579 1583 O
have 14 18 1584 1588 O
bilirubin 19 28 1589 1598 B-clinical_variable
< 29 30 1599 1600 O
1.5 30 33 1600 1603 B-upper_bound
mg 34 36 1604 1606 I-upper_bound
/ 36 37 1606 1607 I-upper_bound
dl 37 39 1607 1609 I-upper_bound

Subjects 0 8 1610 1618 O
with 9 13 1619 1623 O
CNS 14 17 1624 1627 B-cancer
( 18 19 1628 1629 I-cancer
Central 19 26 1629 1636 I-cancer
Nervous 27 34 1637 1644 I-cancer
System 35 41 1645 1651 I-cancer
) 41 42 1651 1652 I-cancer
metastases 43 53 1653 1663 I-cancer
including 54 63 1664 1673 O
brain 64 69 1674 1679 B-cancer
metastases 70 80 1680 1690 I-cancer
who 81 84 1691 1694 O
have 85 89 1695 1699 O
completed 90 99 1700 1709 O
a 100 101 1710 1711 O
course 102 108 1712 1718 O
of 109 111 1719 1721 O
radiotherapy 112 124 1722 1734 B-treatment
are 125 128 1735 1738 O
eligible 129 137 1739 1747 O
for 138 141 1748 1751 O
the 142 145 1752 1755 O
study 146 151 1756 1761 O
provided 152 160 1762 1770 O
they 161 165 1771 1775 O
are 166 169 1776 1779 O
clinically 170 180 1780 1790 O
stable 181 187 1791 1797 O

Symptomatic 0 11 1798 1809 O
congestive 12 22 1810 1820 B-chronic_disease
heart 23 28 1821 1826 I-chronic_disease
failure 29 36 1827 1834 I-chronic_disease
, 36 37 1834 1835 O
unstable 38 46 1836 1844 B-chronic_disease
angina 47 53 1845 1851 I-chronic_disease
pectoris 54 62 1852 1860 I-chronic_disease
, 62 63 1860 1861 O
stroke 64 70 1862 1868 B-chronic_disease
or 71 73 1869 1871 I-chronic_disease
myocardial 74 84 1872 1882 I-chronic_disease
infarction 85 95 1883 1893 I-chronic_disease
within 96 102 1894 1900 O
3 103 104 1901 1902 B-upper_bound
months 105 111 1903 1909 I-upper_bound

Tumor 0 5 1910 1915 B-cancer
must 6 10 1916 1920 O
be 11 13 1921 1923 O
HER2 14 18 1924 1928 B-cancer
- 18 19 1928 1929 O
positive 19 27 1929 1937 O
and 28 31 1938 1941 O
RB 32 34 1942 1944 B-treatment
- 34 35 1944 1945 O
proficient 35 45 1945 1955 O

Uncontrolled 0 12 1956 1968 O
systemic 13 21 1969 1977 B-chronic_disease
illness 22 29 1978 1985 I-chronic_disease
, 29 30 1985 1986 O
including 31 40 1987 1996 O
but 41 44 1997 2000 O
not 45 48 2001 2004 O
limited 49 56 2005 2012 O
to 57 59 2013 2015 O
ongoing 60 67 2016 2023 O
or 68 70 2024 2026 O
active 71 77 2027 2033 B-chronic_disease
infection 78 87 2034 2043 I-chronic_disease

adequate 0 8 2044 2052 O
cardiac 9 16 2053 2060 O
reserve 17 24 2061 2068 O
( 25 26 2069 2070 O
EF>50 26 31 2070 2075 B-clinical_variable
% 31 32 2075 2076 I-lower_bound
) 32 33 2076 2077 O

albumin 0 7 2078 2085 B-clinical_variable
> 8 9 2086 2087 O
3gm 9 12 2087 2090 B-lower_bound
/ 12 13 2090 2091 I-lower_bound
dl 13 15 2091 2093 I-lower_bound

creatinine 0 10 2094 2104 B-clinical_variable
< 11 12 2105 2106 O
1.3mg 12 17 2106 2111 B-upper_bound
/ 17 18 2111 2112 I-upper_bound
dl 18 20 2112 2114 I-upper_bound

oral 0 4 2115 2119 B-treatment
corticosteroids 5 20 2120 2135 I-treatment
for 21 24 2136 2139 O
control 25 32 2140 2147 O
of 33 35 2148 2150 O
CNS 36 39 2151 2154 B-chronic_disease
symptoms 40 48 2155 2163 O

transaminases 0 13 2164 2177 B-clinical_variable
< 14 15 2178 2179 O
2.5x 15 19 2179 2183 B-upper_bound
upper 20 25 2184 2189 I-upper_bound
limit 26 31 2190 2195 I-upper_bound
of 32 34 2196 2198 I-upper_bound
normal 35 41 2199 2205 I-upper_bound

who 0 3 2206 2209 O
have 4 8 2210 2214 O
not 9 12 2215 2218 O
recovered 13 22 2219 2228 O
from 23 27 2229 2233 O
the 28 31 2234 2237 O
adverse 32 39 2238 2245 O
events 40 46 2246 2252 O
to 47 49 2253 2255 O
< 50 51 2256 2257 O
grade 52 57 2258 2263 B-upper_bound
2 58 59 2264 2265 I-upper_bound
due 60 63 2266 2269 O
to 64 66 2270 2272 O
previous 67 75 2273 2281 O
agents 76 82 2282 2288 O
administered 83 95 2289 2301 O
more 96 100 2302 2306 O
than 101 105 2307 2311 O
4 106 107 2312 2313 B-lower_bound
weeks 108 113 2314 2319 I-lower_bound
prior 114 119 2320 2325 I-lower_bound
to 120 122 2326 2328 O
Study 123 128 2329 2334 O
Day 129 132 2335 2338 O
1 133 134 2339 2340 O

